New drug looks good for treating overactive bladder

	Tweet

Once-daily treatment with a drug called solifenacin improves all the major symptoms of overactive bladder, according to a UK study.

“I think it is very important to point out that we need to have more effective treatments for overactive bladder, as not one drug suits all,” Dr. Linda Cardozo from King’s College Hospital, London, UK told Reuters Health. “Hopefully, with good efficacy and a low side effect profile, compliance with therapy will be improved.”

Solifenacin acts on muscarinic receptors in the smooth muscle of the bladder. It was developed in Japan by Yamanouchi, and was submitted for approval by regulators in the US and Europe nearly two years ago under the name Vesicare.

It was approved in Europe in August this year.

In October last year, Yamanouchi received an “approvable letter” from the US Food and Drug Administration, and the company said that after completing the request by the FDA for additional clinical data the drug could be launched this year. Vesicare will be co-promoted with GlaxoSmithKline Plc in the United States.

Cardozo and her colleagues assessed the efficacy and safety of solifenacin in a 12-week trial involving 907 patients with overactive bladder.

Compared with placebo, solifenacin treatment decreased in the average number of urination episodes, urgency episodes, and nighttime episodes, the researchers report the Journal of Urology. Results were somewhat better with the 10-milligram dose than with the 5-milligram dose.

Solifenacin also resulted in greater reductions in the average number of incontinence episodes. In addition, half the patients who were treated with either dose of solifenacin had no incontinence at the end of the study.

Adverse events were typical of this type of drug—dry mouth, constipation, and blurred vision—the researchers note, and there were no safety problems.

“The efficacy of this drug has been shown in all four major symptoms of overactive bladder—daytime frequency, (nighttime urination), urgency, and incontinence,” Cardozo concluded.

“In clinical practice,” she added, “I have been initiating solifenacin therapy at a dose of 5 milligrams daily for a period of 6 weeks, after which the patient is reviewed and given the option to remain on the 5- mg dose or increase to 10-mg dose.”

SOURCE: Journal of Urology, November 2004.

RELATED STORIES:
Drinking less reduces overactive bladder symptoms   External catheters reduce risk of urinary tract infection in men   Hospital Care Varies Greatly for Children with Urinary Tract Infections   More boys than girls wet their beds   UF urologists use robot to shave time off vasectomy reversal   Protein urine test may signal prostate cancer   Alzheimer’s Study Leads to Better Drug for Infections   Concern Over Rapid Rise of Chronic Kidney Disease   Treating vaginosis doesn’t prevent preterm birth   In Predominantly Black Communities, People of all Races Miss Out on Kidney Care   Diet in Affects on Symptoms of Painful Bladder Syndrome   Dialysis Treatments Go Green

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]